Myriad Genetics, Inc.

Myriad Genetics, Inc.

MYGNNYSE / NASDAQHealthcareSmall cap

$5.46-$0.08 (-1.4%)

Last close · Data as of Nov 20, 2026

Market cap
$443.0M
P/E
-1.2x
EV / EBITDA
-1.5x
Revenue
$824.5M
Net margin
-44.4%
ROCE
-11.8%

-20.9% over the last year

Myriad Genetics, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-1.4%
3M
+69.6%
6M
+43.3%
1Y
-20.9%
5Y
-80.5%

52-week range

Day change -$0.08 (-1.4%) from $5.54 to $5.46 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in MYGN, bought on each weekday since 2021.

News & filings

What Myriad Genetics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 366 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are 2.49 times current liabilities.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics.

Read moreShow less

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Sector
Healthcare
Shares outstanding
93.5M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$443.0M
P/E
-1.2x
P/B
1.2x
EV / EBITDA
-1.5x
EV / Sales
0.6x
P/S
0.5x
52-week high
$7.91
52-week low
$2.86

Profitability

Operating margin
-8.2%
Net margin
-44.4%
EBITDA margin
-40.1%
ROE
-99.4%
ROCE
-11.8%
ROIC
-71.0%
ROA
-51.8%
Asset turnover
1.17

Growth

Revenue
$824.5M
Revenue growth, 1Y
-1.6%
Revenue CAGR, 3Y
6.7%
Net profit growth, 1Y
187.4%
Free cash flow
-$25.6M

Solvency

Current ratio
2.49
Debt / Equity
0.57
Debt / Assets
0.30
CFO / Net profit
-0.00
Cash / Market cap
33.8%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$824.5M
Cost of revenue$247.9M
Gross profit$576.6M
Operating expenses$644.4M
Research and development$106.8M
Selling, general and administrative$537.6M
Operating income-$67.8M
Interest and other-$327.3M
Pretax income-$395.1M
Tax and other-$29.2M
Net income-$365.9M

Revenue and net profit

Revenue fell 1.6% in FY2025; net profit is the dashed line.

Myriad Genetics, Inc. revenue and net profit by fiscal year
Myriad Genetics, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$678.4M-$112.0M
FY2023$753.2M-$263.3M
FY2024$837.6M-$127.3M
FY2025$824.5M-$365.9M

Cash flows

FY2025: $1.8M from operations, -$25.6M free after investment (dashed).

Myriad Genetics, Inc. operating and free cash flow by fiscal year
Myriad Genetics, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$106.3M-$151.6M
FY2023-$110.9M-$184.2M
FY2024-$8.7M-$38.4M
FY2025$1.8M-$25.6M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$824.5M-1.6%1Y
EBITDA
-$330.9M
Net profit
-$365.9M
Cash from operations
$1.8M
Free cash flow
-$25.6M
Revenue CAGR, 3Y
6.7%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$824.5M-$330.9M-$365.9M-$25.6M-99.4%-1.6%+187.4%

Monthly returns

Month-by-month returns of MYGN across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$706.6M
Liabilities$338.6M
Equity$368.0M
Paid-in capital$1.5B
Retained earnings-$1.1B

Market cap against peers

8 peers: same sector, nearest by size.

  1. NRC Health$445.1M
  2. Myriad Genetics, Inc. (this company)$443.0M

Peers map

Healthcare companies placed by value, growth and quality; MYGN highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Myriad Genetics, Inc. (this company)0.6x

Not shown (no positive earnings and no EV / Sales): Rezolute, Inc., Neurogene Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Myriad Genetics, Inc.MYGNthis company$443.0M-1.2x1.2x-99.4%-1.5x
Editas Medicine, Inc.EDIT$458.9M-2.9x16.8x-586.6%-2.2x
NRC HealthNRC$445.1M38.4x31.8x82.9%17.2x
Varex Imaging CorporationVREX$440.9M—0.9x-14.9%973.8x
Emergent BioSolutions Inc.EBS$435.5M8.3x0.8x10.1%3.4x
Evolus, Inc.EOLS$434.6M-8.4x-18.8x223.5%-23.8x
Rezolute, Inc.RZLT$434.3M-5.8x2.7x-45.9%-4.3x
Neurogene Inc.NGNE$434.2M-4.8x1.6x-34.1%-3.9x
ClearPoint Neuro, Inc.CLPT$429.5M-16.8x15.3x-91.1%-21.2x
Peer median—-4.8x2.2x-24.5%-3.1x

Year-to-date ROI

MYGN since 1 January, against earlier years.

Historical volatility

MYGN's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Myriad Genetics, Inc. operating margin by fiscal year
Myriad Genetics, Inc. operating margin by fiscal year
DateOperating margin
FY2022-18.2%
FY2023-19.2%
FY2024-10.5%
FY2025-8.2%
LineFY2025
Cost of revenueCost Of Revenue$247.9M
Gross profitGross Profit$576.6M
Operating expensesOperating Expense$644.4M
Research and developmentResearch And Development$106.8M
Total expensesTotal Expenses$892.3M
Pretax incomePretax Income-$395.1M

Learn while you research

Academy chapters picked for Myriad Genetics, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →